No Data
No Data
Tivic Health Names Biotech Industry Veteran Michael K. Handley to Executive Leadership Team
Tivic Health Systems Shares Are Trading Higher After the Company Announced It Acquired the Exclusive License Rights From Statera Biopharma for Its Phase III TLR5 Agonist Entolimod Treatment of Acute Radiation Syndrome.
Express News | Tivic Health Systems Inc - to Pay Statera $1.2 Million in Equity and $300,000 Cash for Entolimod
Tivic Health Acquires Exclusive Worldwide Rights to Phase III TLR5 Agonist From Statera Biopharma
Biostax Corp. and Statera Biopharma, Inc. Reach Mutually Beneficial Dispute Settlement and Amended License Agreement Providing Clearer Clinical and Commercial Pathways for Both Companies
Statera Plans to Merger With Diagnostics Company Worksite